4 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Splenomegaly: new trials by email Literature Review of Splenomegaly trials Research Report on Splenomegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam - Splenomegaly, Myelofibrosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-10-01 | 2026-09-16 |
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Ruxolitinib - BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells | Phase 2 | Active not recruiting | Stanford University | 8 | 2019-11-15 | 2026-09-01 |
| A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 2 | Completed | AbbVie | 191 | 2017-10-31 | 2026-01-20 |
| Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Rigosertib, Questionnaire - Leukemia, Myelofibrosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2017-08-16 | 2020-08-07 |
| Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma Lenalidomide, Obinutuzumab - Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 96 | 2016-12-06 | 2025-06-08 |
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment - Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2015-05-14 | 2019-05-15 |
| Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. ruxolitinib - Thalassemia Major | Phase 2 | Completed | Novartis Pharmaceuticals | 30 | 2014-05-28 | 2017-07-17 |
| Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) Valproic Acid, CT Scan, Blood Sample - ALPS, Hypersplenism | Phase 1 / Phase 2 | Completed | Koneti Rao | 6 | 2008-01-01 | 2013-03-21 |
Primary Myelofibrosis (4) · Hepatomegaly (2) · Anemia (1) · Autoimmune Lymphoproliferative Syndrome (1) · Eosinophilia (1) · Fatigue (1) · Fever (1) · Hypereosinophilic Syndrome (1) · Hypersplenism (1) · Leukemia (1) · Lymphadenopathy (1) · Polycythemia Vera (1) · Thalassemia (1) · Weight Loss (1)
Hypertrophy (8) · Pathological Conditions, Anatomical (8) · Pathological Conditions, Signs and Symptoms (8) · Hemic and Lymphatic Diseases (7) · Hematologic Diseases (6) · Bone Marrow Diseases (4) · Myeloproliferative Disorders (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Genetic Diseases, Inborn (2) · Liver Diseases (2) · Neoplasms (2) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1)
ruxolitinib (4) · Blood Specimen Collection (1) · Busulfan (1) · Cyclophosphamide (1) · Lenalidomide (1) · Levetiracetam (1) · Mesna (1) · Nivolumab (1) · ON 01910 (1) · Surveys and Questionnaires (1) · Tacrolimus (1) · Valproic Acid (1) · eltrombopag (1) · fludarabine (1) · fludarabine phosphate (1)
M.D. Anderson Cancer Center (4) · AbbVie (1) · Koneti Rao (1) · Novartis Pharmaceuticals (1) · Stanford University (1)
United States (7) · Greece (2) · Italy (2) · Australia (1) · Canada (1) · Croatia (1) · Hungary (1) · Israel (1) · Japan (1) · Lebanon (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Taiwan (1) · Thailand (1)
Jorge Cortes, MD (1) · Koneti Rao, MD (1) · Loretta J Nastoupil (1) · Srdan Verstovsek (1) · Uday Popat, MD (1) · William E Shomali, MD (1)
PMID 35180010, PMID 35576960, PMID 40454409, PMID 40517417, PMID 41846295, PMID 42842696
2017 (1), P30CA016672 (1)